Outcomes of immunotherapy vaccine trial show encouraging results for glioblastoma patients
Findings of the DCVax®-L immunotherapy trial have shown promise and suggest that it could help to significantly extend the lives of people diagnosed with glioblastoma – the most aggressive form of brain tumour. The treatment works by using the body's immune system to target the cancer.
People with the diagnosis who took part in the study lived more than twice as long as those on standard treatments in many cases, researchers say. The standard treatment for glioblastoma is surgery, radiotherapy and chemotherapy.